Personal CFO Solutions LLC Buys New Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Personal CFO Solutions LLC bought a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the fourth quarter, Holdings Channel reports. The institutional investor bought 12,230 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

A number of other institutional investors also recently modified their holdings of ACAD. US Bancorp DE lifted its position in shares of ACADIA Pharmaceuticals by 2,084.0% during the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 31,426 shares during the period. Principal Financial Group Inc. lifted its position in shares of ACADIA Pharmaceuticals by 67.8% during the 3rd quarter. Principal Financial Group Inc. now owns 129,551 shares of the biopharmaceutical company’s stock valued at $1,992,000 after acquiring an additional 52,340 shares during the period. Atria Investments Inc raised its holdings in ACADIA Pharmaceuticals by 10.8% during the third quarter. Atria Investments Inc now owns 24,437 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 2,384 shares during the last quarter. Victory Capital Management Inc. raised its holdings in ACADIA Pharmaceuticals by 2.9% during the third quarter. Victory Capital Management Inc. now owns 97,130 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 2,708 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in ACADIA Pharmaceuticals by 26.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 37,429 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 7,872 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on ACAD shares. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley restated an “equal weight” rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Stock Performance

ACAD opened at $17.19 on Wednesday. The firm has a market cap of $2.87 billion, a P/E ratio of 22.04 and a beta of 0.43. The firm has a 50-day moving average of $18.51 and a 200 day moving average of $16.95. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $14.15 and a fifty-two week high of $20.68.

Insider Activity at ACADIA Pharmaceuticals

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 6,167 shares of company stock worth $114,583. 28.30% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.